ALECAlector, Inc.
- GlobeNewswire
Alector Announces Pricing of Underwritten Offering
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (("Alector, NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8
HC Wainwright & Co. analyst Andrew S. Fein maintains Alector with a Buy and raises the price target from $5 to $8. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Alector, Raises Price Target to $8
HC Wainwright & Co. analyst Andrew S. Fein maintains Alector with a Buy and raises the price target from $5 to $8. ...
- Earnings Call Transcripts
Alector Pipeline Webinar: Advancing Next Generation Medicines for Neurodegeneration - ALECTOR INC
Good day and thank you for standing by. Welcome to the Elector Pipeline Webinar, Advancing Next Generation Medicines for Neurodegeneration. At this time, all participants are in a listen-only mode. After the speaker's pr ...
- GlobeNewswire
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program SOUTH SAN FRANCISCO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- ...
- Analyst Upgrades
Morgan Stanley Maintains Underweight on Alector, Raises Price Target to $3
Morgan Stanley analyst Sean Laaman maintains Alector with a Underweight and raises the price target from $2 to $3. ...
- Earnings Call Transcripts
Morgan Stanley 24th Annual Global Healthcare Conference - ALECTOR INC
Good morning, everyone. I'm Sean Lyman, head of U.S. SMITCAP Biotech Equity Research here at Morgan Stanley, and welcome to a Morgan Stanley Global Healthcare Conference. Before we commence, just to make you aware of som ...
- Earnings Call Transcripts
Alector - 1773720 - ALECTOR INC
Good morning, everyone. I'm Sean Lyman, head of U.S. SMITCAP Biotech Equity Research here at Morgan Stanley, and welcome to a Morgan Stanley Global Healthcare Conference. Before we commence, just to make you aware of som ...
- Earnings Call Transcripts
Alector - 1773720 - ALECTOR INC
Good morning, everyone. I'm Sean Lyman, head of U.S. SMITCAP Biotech Equity Research here at Morgan Stanley, and welcome to a Morgan Stanley Global Healthcare Conference. Before we commence, just to make you aware of som ...
- GlobeNewswire
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative ...
- GlobeNewswire
Alector Reports Second Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC-enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s ...
- GlobeNewswire
Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's ...
- GlobeNewswire
Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody ...
- Analyst Upgrades
This Cloudflare Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Wall Street analysts upgraded several stocks, including Cloudflare, Alector, ProPetro, and Atlas Energy. See their ratings and targets here. ...
- Analyst Upgrades
Cantor Fitzgerald Upgrades Alector to Overweight
Cantor Fitzgerald analyst Pete Stavropoulos upgrades Alector from Neutral to Overweight. ...
- Earnings Call Transcripts
Breaking Barriers: Alector Brain Carrier (ABC) Deep Dive & Fireside Chat with ALEC - Cantor
Hello, everyone. I'm Pete Stavropoulos, a biotech analyst at Cantor with another webinar on the blood-brain barrier crossing technologies. It's an exciting time for the field. The blood- brain barrier has been a bottlene ...
- Analyst Upgrades
BTIG Upgrades Alector to Buy, Announces $6 Price Target
BTIG analyst Thomas Shrader upgrades Alector from Neutral to Buy and announces $6 price target. ...
- GlobeNewswire
Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL137 (ABC-enabled anti-amyloid antibody for Alzheimer's ...
- GlobeNewswire
Alector to Participate in the TD Cowen 46th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of ...
- PR Newswire
INVESTOR ALERT: Levi & Korsinsky is Investigating Alec Stock After its Phase 3 INFRONT-3 Clinical Trial Misses Co-Primary Endpoint
Levi & Korsinsky, LLP is investigating Alector, Inc. (NASDAQ: ALEC) following the Company's announcement of topline results from its Phase 3... ...
- GlobeNewswire
Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of ...
- GlobeNewswire
Alector to Participate in the Bank of America CNS Therapeutics Conference
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of ...
- GlobeNewswire
Alector Reports Third Quarter 2025 Financial Results and Provides Business Update
Selected lead candidates AL137 for the company's Alector Brain Carrier (ABC)-enabled anti-amyloid beta antibody in Alzheimer's disease, and AL050 for its ABC-enabled GCase enzyme replacement therapy in Parkinson's ...
- PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alector, Inc. - ALEC
Pomerantz LLP is investigating claims on behalf of investors of Alector, Inc. ("Alector" or the "Company") (NASDAQ: ALEC). Such investors are advised ... ...
- Analyst Upgrades
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff. ...